Skip to main content
Fig. 7 | Molecular Medicine

Fig. 7

From: Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms

Fig. 7

In vivo antitumor activities of Oligo AS administered alone or in combination with HCPT and 5-Fu in mice bearing human colon cancer DLD-1 xenografts. Doses for Oligo AS alone were 1, 10, and 20 mg/kg/day (panel A). Doses in combination therapy were the same as that with LS174T model. In a dose-dependent manner, Oligo AS inhibited DLD-1 tumor growth (panel A). Additive or synergistic therapeutic effects were observed in combination therapy with Oligo AS and HCPT (panel B) or 5-FU (panel C). The therapeutic effectiveness for each treatment is summarized in Table 3. The host toxicity (survival rate) is summarized in Table 4.

Back to article page

Molecular Medicine

ISSN: 1528-3658